A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Phase 1

Recruiting

• Conditions: Atopic Dermatitis Eczema; Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

• Registration Number: CTIS2022-501476-25-00
• Lead Sponsor: Eli Lilly & Co.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-03-14
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 291

Inclusion Criteria

Have Atopic Dermatitis for at least 6 months if younger than 6 years old or 1 year if older than 6 years., 6 months to 6 years old and weigh over 6 kilograms., 12 to 18 years old and weigh less than 40 kilograms., A parent or legal guardian must be able to sign the consent document and follow to the guidelines of the study., And meet other additional conditions at the time of the first visit.

Exclusion Criteria

Have been in a similar study with a similar drug or received a forbidden treatment within the last 2 - 8 weeks., Be pregnant or breastfeeding., Have had previous reaction to the study drug or the ointments or cremes used in this study., Have a severe or current infection that requires strong antibiotics., Have a history of or have a current disease, or type of illness that your doctor believes could affect your safety., Have an addiction to drugs or alcohol.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified